360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

bevacizumab

Type: Keyphrase

Name: bevacizumab

First reported 10 hours ago - Updated 10 hours ago - 1 reports

National Institute for Health & Clinical Excellence

Will U.K. watchdogs change their minds on Avastin in ovarian cancer?

The U.K.'s cost-effectiveness police have been arresting Roche's ($RHHBY) Avastin development efforts once again. As Cover magazine reports, the National Institute for Health and Clinical Excellence has nixed two proposed uses for the drug in ovarian ... [Published FiercePharma - 10 hours ago]

Entities: Avastin, National Institute for Health & Clinical Excell..., Ovarian Cancer

First reported 15 hours ago - Updated 15 hours ago - 1 reports

NHS

NICE cuts funding for advanced ovarian cancer

The National Institute for Health and Care Excellence (NICE) has advised the NHS against funding for a drug used for advanced ovarian cancer.In two separate pieces of final guidance published for the health service, NICE concludes that funding the drug, ... [Published Cover Magazine - 15 hours ago]

Entities: Ovarian Cancer, bevacizumab, NHS, Drugs, Chemotherapy

First reported May 20 2013 - Updated May 20 2013 - 1 reports

MoH warns of harmful effects of cancer drug

Abu Dhabi: The Ministry of Health (MoH) has warned of a drug known as Avastin (Bevacizumab) which is used as a treatment for cancer.The drug could cause necrotising fasciitis, commonly known as the flesh-eating disease or flesh-eating bacteria syndrome. ... [Published The Gulf Today - May 20 2013]

Entities: antineoplastic, Drugs, Al Amiri, bevacizumab

First reported May 20 2013 - Updated May 20 2013 - 1 reports

TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annual Meeting

SOURCE TRACON PharmaceuticalsSAN DIEGOIn collaboration with the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP), TRACON has initiated two randomized Phase 2b studies to evaluate TRC105 in combination with bevacizumab (Avastin®) ... [Published KiiiTV3.com - May 20 2013]

Entities: Tracon, Avastin, Clinical trials

First reported May 17 2013 - Updated May 18 2013 - 2 reports

Reed Elsevier

New Study Pinpoints Biochemical Mechanism Underlying Fibrosis Following Glaucoma Surgery

is a world-leadingprovider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, includingThe Lancet andCell, and close ... [Published Justmeans - May 17 2013]

Entities: Glaucoma, Elsevier BV, Reed Elsevier, fibrosis, Pathology

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Adding Cetuximab Promising in Making Colorectal Liver-Specific Metastases Resectable

A Phase III trial from China has found that adding the monoclonal antibody cetuximab to chemotherapy converted some previously inoperable colorectal liver-specific metastases into those that could be resected, shrinking tumors and significantly increasing ... [Published Oncology Times - May 18 2013]

Entities: cetuximab, Patient, Metastases, liver metastases

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Study: Off-Label Anticancer Drug Use Less than Had Been Thought

Off-label chemotherapy use, frequently pointed to as a big factor in America's high cancer treatment costs, accounts for an estimated 30 percent of the total U.S. sales of the most common patent-protected therapies, according to the first-ever analysis ... [Published Oncology Times - May 18 2013]

Entities: bevacizumab, Chemotherapy, Breast Cancer, Cancer

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Immunology-Based Platforms Launch Novel Treatments in Ovarian Cancer

WASHINGTON—Activity at any level is a welcomed outcome in patients with platinum-resistant ovarian cancer. Two Phase I trials reported here at the American Association for Cancer Research Annual Meeting showed responses in heavily pretreated patients, ... [Published Oncology Times - May 18 2013]

Entities: Tumor, Ovarian Cancer, Immunology, Patient

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells

Background/aimsVascular endothelial growth factor (VEGF) is a key factor in the pathogenesis of neovascular retinal diseases including age-related macular degeneration. VEGF inhibitors including ranibizumab, pegaptanib or bevacizumab improve retinal morphology ... [Published British Journal of Ophthalmology - May 18 2013]

Entities: Aflibercept, ranibizumab, bevacizumab

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Study Findings from G. Bisagni et al Broaden Understanding of Breast Cancer

(NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Breast Cancer. According to news reporting originating from Cremona, Italy, by NewsRx correspondents, research stated, "Therapeutic approach ... [Published NewsRX - May 17 2013]

Entities: Breast Cancer, bevacizumab, Cremona (Italy), capecitabine, maintenance therapy

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Mathematical modelling against tumour growth

Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumour ... [Published Scientific Computing World - May 17 2013]

Entities: Tumor, Phase III, bevacizumab, Oncology

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Progress of VGX-100 Phase 1 trial to be presented at ASCO

ASX and Media release17 May 2013Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY), through its 100% owned subsidiary Ceres Oncology Pty Ltd, is pleased to announce that a clinical update for its anti-VEGF-C antibody, VGX-100, in patients with advanced ... [Published Noodls - May 17 2013]

Entities: lymphatic vessel, Phase I, Australian Securities Exchange, Oncology

Quotes

...ovarian cancer treatment and we're naturally disappointed that we can't recommend it in either instance," Dillon said (as quoted by Cover). "Unfortunately, the evidence provided to the Appraisal Committee--which developed these two pieces of guidance for NICE--highlighted that, in both cases, bevacizumab was not cost-effective."

Will U.K. watchdogs change their minds on Avastin in ovarian cancer? [Published FiercePharma - 10 hours ago]

Sir Andrew Dillon, chief executive at NICE, said: "The NHS has finite resources so it's important that only the most cost-effective treatments - drugs that work well considering their cost and potential side-effects - are recommended."

NICE cuts funding for advanced ovarian cancer [Published Cover Magazine - 15 hours ago]

"Based on the data from our Phase 1b study of TRC105 in combination with Avastin, which we will discuss later this month at ASCO, we are proceeding forward with an aggressive clinical development plan for TRC105" said Charles Theuer

TRACON Pharmaceuticals Announces TRC105 Clinical Trials, Abstract Presentations at 2013 ASCO Annu ... [Published KiiiTV3.com - May 20 2013]

...Mary's Hospital and the College of Medicine of the Catholic University of Korea. "Our present study shows that VEGF induces TGF-β1 production, and inhibiting VEGF reduces TFG-β1 levels - and decreases subconjunctival fibrosis after trabeculectomy." Trabeculectomy is the surgical process by which a filtering bleb is made under the conjunctival and subconjunctival space for the aqueous humor to be...

Study: VEGF inhibitor appears to improve glaucoma surgical outcomes [Published News-Medical.Net - May 18 2013]

More Content

sort by: Date \| Relevance
Will U.K. watchdogs change their minds on Avast... [Published FiercePharma - 10 hours ago]
NICE cuts funding for advanced ovarian cancer [Published Cover Magazine - 15 hours ago]
MoH warns of harmful effects of cancer drug [Published The Gulf Today - May 20 2013]
TRACON Pharmaceuticals Announces TRC105 Clinica... [Published KiiiTV3.com - May 20 2013]
Study: VEGF inhibitor appears to improve glauco... [Published News-Medical.Net - May 18 2013]
How Do I Treat Patients with Locally Advanced G... [Published Oncology Times - May 18 2013]
Study: Off-Label Anticancer Drug Use Less than ... [Published Oncology Times - May 18 2013]
Adding Cetuximab Promising in Making Colorectal... [Published Oncology Times - May 18 2013]
Immunology-Based Platforms Launch Novel Treatme... [Published Oncology Times - May 18 2013]
Comparative toxicity and proliferation testing ... [Published British Journal of Ophthalmology - May 18 2013]
New Study Pinpoints Biochemical Mechanism Under... [Published Justmeans - May 17 2013]
New study pinpoints biochemical mechanism under... [Published EurekAlert! - May 17 2013]
New Study Pinpoints Biochemical Mechanism Under... [Published theCSRfeed - May 17 2013]
Study Findings from G. Bisagni et al Broaden Un... [Published NewsRX - May 17 2013]
The anti-VEGF dilemma May 17 2013 The licensing... [Published Optometry Today - May 17 2013]
Mathematical modelling against tumour growth [Published Scientific Computing World - May 17 2013]
Amgen says new analyses identify predictive bio... [Published PharmaBiz - May 17 2013]
Novel Two-step Immunotherapy Shows Promise in R... [Published CancerConnect.com - May 17 2013]
Progress of VGX-100 Phase 1 trial to be present... [Published Noodls - May 17 2013]
Advances in the Systemic Treatment of Metastati... [Published Consultant Live - May 16 2013]
Cancer Metabolism as a Therapeutic Target: Meta... [Published Cancernetwork.com - May 16 2013]
Diagnosis and Management of Carotid Artery Disease [Published Review of Optometry - May 16 2013]
Early Results Robust for New PD-L1 Immunotherap... [Published OncLive - May 16 2013]
New Analyses Identify Predictive Biomarkers For... [Published Individual.com - May 15 2013]
Roche to present important new data reflecting ... [Published Noodls - May 15 2013]
ROCHE HOLDING LTD.: Roche to present important ... [Published 4 Traders - May 15 2013]
Genentech to Present Important New Data Reflect... [Published EquityJungle - v0.1 - May 15 2013]
Preview of ASCO 2013: The Abstracts Expected to... [Published Oncology Business Review - May 14 2013]
Zr-89 bevacizumab could be a player in PET dete... [Published MolecularImaging.net - May 14 2013]
China : TO Sell Vectibix in China Amgen forms J... [Published Equities.com - May 13 2013]

Blogs

sort by: Date \| Relevance
Genentech to Present Important New Data Reflect... [Published EquityJungle - v0.1 - May 15 2013] Filed under: Investing Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers -- -- Early Stage Data on Investigational ...
Deals of the Week: With Option Deal, Forest Kee... [Published The IN VIVO Blog - May 10 2013] It’s an optimistic time for pharma dealmakers, with the Dow and the Nasdaq Biotechnology Index climbing, buyers sitting on big piles of cash, and the IPO window as wide-open as it’s been in years. But for smaller companies that have long lamented that ...
NICE issues latest draft guidance on bevacizuma... [Published NICE \| National Institute for Health and Clinic ... - Apr 19 2013] The cancer treatment bevacizumab (Avastin, Roche) is not recommended as an NHS treatment for a type of recurrent, advanced ovarian cancer*, according to the latest draft guidance published by the National Institute for Health and Care Excellence (NIC ...
NICE draft guidance does not recommend bevacizu... [Published NICE \| National Institute for Health and Clinic ... - Mar 25 2013] New, draft guidance issued today (25 March) by the National Institute for Health and Clinical Excellence (NICE) does not recommend bevacizumab (also known as Avastin and manufactured by Roche) for NHS use as an ovarian cancer treatment. ...
4 Healthcare Stock Stories for The Day Before F... [Published Wall St. Cheat Sheet - Feb 07 2013] Eli Lilly and Company ( NYSE:LLY ): Closing price $53.74 Lilly will cease the development of its experimental rheumatoid arthritis drug tabalumab, almost two months after data from a late-stage trial indicated that the drug was unlikely to prove ...

Press Releases

sort by: Date \| Relevance
Research and Markets: The Complete Guide to Com... [Published Business Wire - May 02 2013]
OXiGENE Announces Completion of Enrollment of Z... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Research and Markets: Competitor Analysis: VEGF... [Published Business Wire Health News - Mar 27 2013]
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) ... [Published GlobeNewswire: Advertising News - Feb 06 2013]
Amgen Announces Results From Phase 3 PAVES Stud... [Published PR Newswire: General Business - Jan 26 2013]